Biotech Business - December 14, 2016
FDA accepts AstraZeneca’s biologics license application
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb), and granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for the second quarter of 2017. […]
Collaboration - October 16, 2013
Taris Biomedical and AstraZeneca in bladder cancer pact
TARIS Biomedical enters research collaboration with AstraZeneca for improved bladder cancer treatments. TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the […]